Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl(4)-induced liver fibrogenesis mouse model

Hepatic fibrosis, a progressive chronic disease mainly caused by hepatitis viral infections, alcohol abuse or metabolic syndrome leading to liver dysfunction and is the growing cause of mortality worldwide. Tyrosine kinase inhibitor BIBF1120 (Nintedanib) has been evaluated in clinical trials for idi...

Descripción completa

Detalles Bibliográficos
Autores principales: Öztürk Akcora, Büsra, Storm, Gert, Prakash, Jai, Bansal, Ruchi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349608/
https://www.ncbi.nlm.nih.gov/pubmed/28291245
http://dx.doi.org/10.1038/srep44545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349608/
https://www.ncbi.nlm.nih.gov/pubmed/28291245
http://dx.doi.org/10.1038/srep44545

Ejemplares similares